Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The Akt pathway in human breast cancer: a tissue-array-based analysis.

Shikha Bose1, Sindhu Chandran, James M Mirocha

  • 1Department of Pathology, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA. BoseS@cshs.org

Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc
|December 13, 2005
PubMed
Summary

The Akt pathway is activated early in breast cancer, even in the in-situ stage. PTEN loss and S6 overexpression correlate with disease progression, impacting targeted therapy development.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

CTLA4-Ig + Anti-IL-6/IL-6R Treatment Results in Long-term Allograft Survival and Function in Highly HLA-sensitized Patients.

Transplantation direct·2026
Same author

Does Insulin Resistance Predict Lower Urinary Tract Symptoms? Results From the Reduction by Dutasteride of Prostate Cancer (REDUCE) Trial.

The Prostate·2026
Same author

Consensus-based Recommendations on the Management of Immunosuppression After Squamous Cell Carcinoma Diagnosis in Kidney Transplant Recipients: An International Delphi Consensus Statement.

Transplantation direct·2025
Same author

Pharmacokinetics, lineage identity, and trafficking of ex vivo expanded polyclonal regulatory T cells in a prospective randomized clinical trial of kidney transplant recipients with allograft inflammation.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2025
Same author

Tocilizumab Treatment for Microvascular Inflammation and Chronic Active Antibody-mediated Rejection in Kidney Transplantation.

Transplantation direct·2025
Same author

Interstitial Fibrosis in Kidney Allografts: Know Thy Enemy.

Kidney international reports·2025

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • The Akt pathway regulates cell proliferation and survival, and its deregulation is common in cancers.
  • Kinase inhibitors targeting the Akt pathway have shown promise in reducing tumor growth.

Purpose of the Study:

  • To investigate the Akt pathway's status in human breast cancers.
  • To examine relationships between Akt pathway component proteins and their correlation with tumor characteristics and patient outcomes.

Main Methods:

  • Immunohistochemistry was used to evaluate expression levels of PTEN, phosphorylated Akt, FKHR, mTOR, S6, and cyclin D1.
  • Analysis was performed on a tissue microarray of 145 invasive breast cancers and 140 ductal carcinomas in-situ.
  • Statistical correlations were made between protein expression, tumor characteristics, and disease outcome.

Related Experiment Videos

Main Results:

  • Akt pathway activation was observed early, in the in-situ stage of breast cancer.
  • PTEN loss did not consistently correlate with Akt activation, suggesting alternative mechanisms.
  • PTEN loss and S6 overexpression increased with disease progression from in-situ to invasive stages.
  • Cyclin D1 overexpression in low-grade tumors correlated with longer disease-free survival.
  • mTOR overexpression was associated with a threefold increased risk of disease recurrence.

Conclusions:

  • The Akt pathway is activated early in breast cancer development.
  • Aberrant expression of PTEN, S6, and mTOR are associated with breast cancer progression and recurrence risk.
  • Findings support the potential of targeted therapies and highlight cyclin D1's prognostic value.